Effects of uwhangchungsimwon on cell viability, proliferation, and gene expression of human neuronal cell line IMR32

American Journal of Chinese Medicine

Volumn 29, Issue 3-4, 2001, Pages 445-458

  Song, Keun ^a   Kirn, Young Suk ^a   Moon, Sang Kwan ^a   Ko, Chang Nam ^a   Cho, Ki Ho ^a   Bae, Hyung Sup ^a   Lee, Kyung Sup ^a  

^a Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BAX PROTEIN, HUMAN; BCL2L1 PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN; CDKN1A PROTEIN, HUMAN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; CYCLINE; HERBACEOUS AGENT; HISTONE; NEUROPROTECTIVE AGENT; ONCOPROTEIN; OSTEOGENIC PROTEIN 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA; UWHANGCHUNGSIMWON;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CYTOLOGY; DRUG EFFECT; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MEDICINAL PLANT; NERVE CELL; NEUROBLASTOMA; ONCOGENE; ONCOGENE MYC;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BONE MORPHOGENETIC PROTEINS; CELL CYCLE; CELL DIVISION; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DRUGS, CHINESE HERBAL; GENE EXPRESSION; GENES, FOS; GENES, MYC; HISTONES; HUMANS; NEUROBLASTOMA; NEURONS; NEUROPROTECTIVE AGENTS; PLANTS, MEDICINAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035747959     PISSN: 0192415X     EISSN: None     Source Type: Journal    
DOI: 10.1142/s0192415x01000460     Document Type: Article

References (48)

1. Alessi, F., S. Quarta, M. Savio, F. Riva, L. Rossi, L.A. Stivala, A.I. Scovassi, L. Meijer and E. Prospcri. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in Gl phase by specific inhibition of CDK2 kinase activity. Exp. Cell Res. 245: 8-18, 1998.
2. Barak, Y., T. Juven, R. Haffner and M. Oren. Mdm-2 expression is induced by wild-type p53 activity, EMBO 12:461168, 1993.
3. Borellini, F. and R.I. Glazer. Induction of Spl-p5J binding heterocomplexes during granulocyte macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell lineTF-1, J. Biol Chem. 268: 7923-7928, 1993.
4. Campisi, J., G. Morreo and A.B. Pardee. Kinetics of Gl transit following brief starvation for serum factors, Exp. Cell Res. 152: 459-466, 1984.
5. Chi, S.G., R.W. Devere, F.J. Meyers, D. Siders, F. Lee and P.H. Gumerlock. p53 in prostate: frequent expressed transition mutations, J. Natl. Cancer Inst. 86: 926-933, 1994.
6. Chin. K.V., K. Ueda, I. Pastan and M.M. Gottesman. Modulation of activity of the promoter of the human MDR1 gene by ras andp53, Science (Washington DC) 255: 459-462, 1992.
7. Cho, K.H. and K.S. Lee. Clinical observation on primary intracerebral hemorrhage, J. Korean Oriental Medical Society 7(1): 129, 1986.
8. Cho, T.S., S.M. Lee, E.B. Lee, S.I. Cho, Y.K. Kim, D.H. Shin and O.K. Park. Pharmacological actions of new Uhwangchungsimwon pill on cerebral ischemia and central nervous system, Yakhak Hoeji 41: 817-828, 1997.
9. Cho, T.S, S.M. Lee, N.D. Kim, I.H. Huh, H.S. Ann, K.I. Kwon, S.K. Park, S.H. Shim, D.H. Shin and O.K. Park. Pharmacological actions of new Uhwangchungsimwon pill on cardiovascular system, Yakhak Hoeji 41: 802-816,1997.
10. Chomczynski, P. and N. Sacchi. Single-step method of RNA isolation by acid-guanidinium thiocyanate-phcnol-chloroform extraction, Anal. Biochem. 162: 156-159, 1987.
11. Cole, S.P. Rapid chemosensitivity testing of human lung tumor cells using the MTT assay, Cancer chemother Pharmacology 17: 259-263, 1986.
12. Collins M.K.L. and A.L. Rivas. The control of apoptosis in mammalian cells, Trends in Cell Biology 18: 307-309,1993.
13. Datto, M.B., Y. Li, J.F. Panus, D.J. Howe, Y. Xiong and X.F. Wang. Transforming growth factor induces the cyclin-dependent kinase inhibitor p21 through a/?53-independent mechanism, Proc. Natl Acad. Sei. USA 92: 5545-5549, 1995.
14. El-Deiry, W.S., J.W. Harper, P.M. O'Connor, V.E. Velculescu, C.E. Canman, J. Jackman, J.A. Pietenpol, M. Brrrell, D.E. Hill, Y. Wang, K.G. Wiman, W.E. Mercer, M.B. Kastan, K.W. Kohn, S.J. Elledge, K.W. Kinzler and B. Vogelstein. (Fo/7/CIPl is induced in/?53-mediated Gl arrest and apoptosis, Cancer Res. 54: 1169-1174, 1994.
15. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler and B. Vogelstein. Wafl, a potential mediator ofp53 tumor suppression. Cell 75: 817-825,1993.
16. Flores-Rozas, H., Z. Kelman, F.B. Dean, Z.Q. Pan, J.W. Harper, S.J. Elledge, M. O'donnell and J. Hurwitz. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase holoenzyme, Proc. Natl. Acad. Sei. USA 91: 8655-8659,1994.
17. Ginsberg, D., F. Mechta, M. Yaniv and M. Orcn. \Vild-typep53 can down-modulate the activity of various promoters, Proc. Natl. Acad Sei. USA 88: 9979-9983, 1991.
18. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi and S.J. Elledge. The p21 cdk-interacting protein Cipl is a potent inhibitor of Gl cyclin-dependent kinases, Cell 75: 805-816, 1993.
19. Hong, N.D., N.J. Kim, and K.S. Kim. Studies on the efficacy of combined preparation of crude drugs-Effect of Uhwangchungsimwon on the cardiovascular system. Kor. J. Pharmacology 18: 4,241-248,1987.
20. Kane, S.E., I. Pastan and M.M. Gottesman. Genetic basis of multidrug resistance of tumor cells, J. Bioenerg. Biomembr. 22: 593-618, 1990.
21. Kastan, M.B., Q. Zhan, W.S. El-Deiry, F. Carrier, T. Jacks, W.V. Walsh, B.S. Plunkett and A.J. Jr. Fornace. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia, Cell 71: 587-597, 1992.
22. Kawamata, T., J. Ren, T.C. Chan, M. Charette, S.P. inklestein. Intracisternal osteogenic protein-1 enhances functional recovery following focal stroke, Neuroreport 9:144-1445,1998.
23. Kem, S.E., J.A. Pietenpol, S. Thiagalingam, A. Seymour, K.W. Kinzler and B. Vogelstein. Oncogenic forms ofp53 inhibit p53-regulated gene expression, Science (Washington DC) 256: 827-830, 1992.
24. Kim, Y.S., S.K. Moon, C.N. Ko, K.H. Joh, H.S. Bae and, K.S. Lee. Effects of Uwhangchungsimwon on cerebral blood flow and systemic blood pressure in humans. Journal of Korean Oriental Internal Medicine 20: 222-231, 1999.
25. Ko, C.N., S.K. Moon, K.H. Cho, K.S. Cho, Y.S. Kim, H.S. Bae and K.S. Lee. Effects of Uhwangchungsimwon on the isolated rat hearts under Langendorff apparatus. Journal of Oriental Medicine 2(\): 33-43, 1997.
26. Kwon, D.I., C.N. Ko, K.H. Cho, Y.S. Kim, H.S. Bae and K.S. Lee. Clinical observation on the admitted patients of department of cardiac internal medicine of oriental hospital, J. KyimgHee Univ. Med. Center 12(2): 200, 1996.
27. Lane, D.P.pSS, guardian of the genome, Nature (Lond.) 358: 15-16,1992.
28. Lein, P., M. Johnson, X. Quo, D. Rueger and D. Higgins. Osteogenic protein-1 induces dendritic growth in rat sympathetic neurons, Neuron 15: 597-605, 1995.
29. Levine, A.J. The/?53 tumor suppressor gene and product, Cancer Surveys 12: 59-79, 1992.
30. Mack, D.H., J. Vartikar, J.M. Pipas and L.A. Laimins. A Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type/?53, Nature (Lond.) 363: 281-283, 1993.
31. Matsubara, T. Pharmacological studies of Civetone, a fragnant component, in Civet- comparison with actions of Muscone on cardiovascular and respiratory systems, Busan Yakhak Yeonbo 17: 42-48, 1990.
32. Mercer, W.E., M.T. Shields, D. Lin, E. Appella and S.J. Ullrich. Growth suppression induced by \\i\d-typep53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression, Proc. Natl. Acad. Sei. USA 88: 1958-1962,1991.
33. Mercer, W.E., M.T. Shields, M. Amin, G.J. Sauve, E. Appella, J.W. Romano and S.J. Ullrich. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53, Proc. Natl. Acad. Sei. USA 87: 6166-6170, 1990.
34. Michieli, P., M. Chedid, D. Lin, J.H. Pierce, W.E. Mercer and D. Givol. Induction of WAF1ICIVI by a -independent pathway, Cancer Res. 54: 3391-3395, 1994.
35. Miyashita, T., M. Harigai, M. Hanada and J.C. Reed. Identification of apJJ-dependent negative response element in the Bcl-2 gene, Cancer Res. 54: 3131-3135,1994.
36. Nakanishi, M., G.R. Adami, R.S. Robetorye, A. Noda, S.F. Venable, D. Dimitrov, O.M. Pereira-Smith and J.R. Smith. Exit from GO and entry into the cell cycle of cells expressing p21Sdil antisense RNA, Proc. Natl. Acad. Sei. USA 92: 4352-4356, 1995.
37. Pendes, G., F.E. Jensen, P. Edgecomb, D.C. Ruegcr and M.E. Charness. Neuroprotective effect of human osteogenic protein-1 in a rat model of cerebral hypoxia/ischemia, Neurosci Lett. 87: 21-24,1995.
38. Seto, E., A. Usheva, G.P. Zambetti, J. Momand, N. Horikoshi, R. Weinmann, A.J. Levine and T. Shenk. Wild-type p53 binds to the TATA-binding protein and represses transcription, Proc. Natl. Acad. Sei. USA 89: 12028-12032, 1992.
39. So, C.S., R.E. Purdy, R.A. Giolli, R.H. Blanks. The in vitro characterization of the vasodilating action of Woo Hwang Chung Sim Won. The 9th international congress of oriental medicine (The 9thICOM). 1998.
40. Soloff, B.L., W.A. Nagle, A.J. Moss, K.J. Henle and J.T. Crawford. Apoptosis induced by cold shock in vitro is dependent on cell growth phase. Biochem. Biophys. Res. Commun. 145: 876-883,1987.
41. Traganos, F., Juan, G., and Z. Darzynkiewicz. Cell-cycle analysis of drug-treated cells. Methods Mol. Biol. 95: 229-240,2001.
42. Vukicevic, S., V. Basic, D. Rogic, N. Basic, M.S. Shih, A. Shepard, D. Jin, B. Dattatreyamurty, W. Jones, H. Dorai, S. Ryan, D. Griffiths, J. Maliakal, M. Jelic, M. Pastorcic, A. Stavljenic and T.K. sampath. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischémie acute renal failure in rat, J. Clin. Invest. 102: 202-214, 1998.
43. Wang, E., M.J. Lee and S. Pandey. Control of fibroblast senescence and activation of programmed cell death, J. Cell. Biochem. 54: 432-439, 1994.
44. Weintraub, H., S. Hauschka and S.J. Tapscott. The MCK enhancer contains a p53 responsive element, Proc. Natl. Acad. Sei. USA 88: 4570-4574, 1991.
45. Williams, G.T. and C.A. Smith. Molecular regulation of apoptosis: genetic controls on cell death, Cell 74: 777-779, 1993.
46. Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi and M. Oren. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interlcukin-6, Nature (Lond.) 352:345-347,1991.
47. Yun, J.G., K.H. Cho, Y.S. Kirn and K.S. Lee. Clinical observation on C.V.A, J. Korean Oriental Internal Medicine 10(1): 25, 1989.
48. Zambetti, G., J. Bargonetti, K. Walker, C. Prives and A.J. Levine. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element, Genes Dev. 6: 1143-1152, 1992.